KUALA LUMPUR (May 25): CIMB IB Research has maintained its “Reduce” rating on Hovid Bhd at 35 sen with a higher target price of 32 sen (from 30 sen) and said Hovid’s 9MFY17 core net profit were below expectations, at only 35% of house and 26% of Bloomberg consensus full-year estimates.
In a note May 24, the research house said Hovid’s 9MFY17 revenue and net profit declined by 2.6% and 54.4% y-o-y, respectively.
It said this was attributed to: i) production loss in 3QFY17 due to suspension of both its manufacturing licences, ii) lower sales volume, and iii) higher operating costs.
“Licence secured since for both plants at Chemor (March 6) and Ipoh (May 5); full production resumed.
“Maintain Reduce, but SOP-based target price raised to 32 sen. We are removing the 10% discount to its 5-year mean P/E, in tandem with the reissuance of both licences,” it said.
Err actually i was thinking that because it is Ramadan month. People r withdrawing out for the coming Raya. Since other stocks also encounter a drop here.
Well, personally I think that license withdrawal is not a big issue. They have subsidiaries and possible merges or acquisitions with other company to obtain these licenses again.
What i see is that their revenue is still maintain around the same level currently, putting off rumors aside.
P.E and EPS is not a good referencing for penny stocks or low cost stocks. Through my observation, market sentiment is the way of investment for such stocks, at least for the malaysia stock market.
Hovid been in Malaysia since 1940 and started from a humble beginning. They been venturing into manufacturing for medicines and expanding their horizons in medicinal line and it is getting better. They have approved by Unicef for their drugs and this company have vast opportunity in future.
Below was the real problem occured when MOH revoked their licensing.
It was a technnical error or labeling. Medicine is still the same. No harm been done.
"HOVID’S PRODUCT RECALL OF TERNOLOL 50" Hovid would like to express our sincere apologies to the patients who have purchased Ternolol 50mg Tablets with batch no. BG 04645 from any clinics, pharmacies or hospitals. The batch for recall contains boxes labelled as “Ternolol 50”, however, (some of) the blisters stated the product as “Ternolol Tab 100mg”.
The actual product packed within the boxes is Ternolol 50mg which corresponds to the box label. The tablets contain active atenolol ingredients which are prescribed for hypertension treatment. We are recalling the concerned product from the market. Patients may contact our pharmacist at Hovid Hotline 05-5060690 (Mon-Fri, 8.00am- 6.00pm) for any clarification or questions they may have. Our office will be closed on Saturday & Sunday. However, you may still be able to contact the following personnel on Saturday & Sunday. Chin Lai Ting 012-5070396 Choong Foo Wah 019-2771315 Cheah Wai Kit 012-6566030 Nor Hisham Yusop 012-7384114 Thomas Wong 016-5202118 We will assist those who are affected in handling their returns.
Unknown404 I still rmb i got trap in aax at 1.27, the highest price that time. But that case is different, they are losing money and the currency trade is uncertain.
But this one is good in terms that the revenue is maintained all the time. I'll put a cut lost if it falls below 29cents. The rebounding chance is higher than a falling price.
Like ppl say, market sentiment not good mah. You see other stocks also falling this week.
If it really hover around .33 n .34 till year end then that's good news since it built a support line on .33 which means it would have a big leap anytime.
Just went to take a quick look at the new R&D building at Bayan Lepas Penang during my lunch time. The car parks started to fill up with cars, might be started in operation or soon in operation compare to my last visit.
how can tp of 0.2 make any sense.. when there is a double in capacity from the dual plant which is not included in the current books. on top of that, their sales figure is increasing.
careful to those SOUR GRAPES' comments!...waiting 2 buy CHEAP from those PANIC SELLERS!...HOLD TIGHT AND U WILL BE REWARDED WITH HANDSOME GAINS!!!!!!!!!!!!!!
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Report Abuse
Please Sign In to report this post as abuse.
Market Buzz
No result.
Featured Posts
MQ Trader
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: Supreme Consolidated Resources Berhad, a distributor and warehouser of F&B products, aims to list on the ACE Market!
MQ Trader 575 views | 11 d ago
0:17
New IPO: O&G healthcare service provider, Metro Healthcare Berhad aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
lowbuyhighsell
235 posts
Posted by lowbuyhighsell > 2017-05-25 09:17 | Report Abuse
KUALA LUMPUR (May 25): CIMB IB Research has maintained its “Reduce” rating on Hovid Bhd at 35 sen with a higher target price of 32 sen (from 30 sen) and said Hovid’s 9MFY17 core net profit were below expectations, at only 35% of house and 26% of Bloomberg consensus full-year estimates.
In a note May 24, the research house said Hovid’s 9MFY17 revenue and net profit declined by 2.6% and 54.4% y-o-y, respectively.
It said this was attributed to: i) production loss in 3QFY17 due to suspension of both its manufacturing licences, ii) lower sales volume, and iii) higher operating costs.
“Licence secured since for both plants at Chemor (March 6) and Ipoh (May 5); full production resumed.
“Maintain Reduce, but SOP-based target price raised to 32 sen. We are removing the 10% discount to its 5-year mean P/E, in tandem with the reissuance of both licences,” it said.